Slayback Pharma is a specialty pharmaceutical company focusing on complex generic pharmaceutical products, particularly injectables and other non-solid oral products. The company stands out with a unique portfolio of complex generics curated through smart product selection, execution, and an extensive network of contract R&D laboratories and manufacturing organizations. Founded in 2011 and headquartered in the United States, Slayback Pharma has demonstrated its commitment to innovation through sophisticated manufacturing and innovative drug delivery technologies. Their most recent milestone was a $50.00M Series B investment from Everstone Capital in January 2020. With their forward-thinking approach and strong industry position, Slayback Pharma is well poised to make a significant impact in the Biopharma, Manufacturing, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $50.00M | 1 |
|
06 Jan 2020 |
| Private Equity Round | $60.00M | 1 | Kohlberg Kravis Roberts | 05 Jan 2017 |
No recent news or press coverage available for Slayback Pharma.
We care about your data, and we'd love to use cookies make your experience better.
